A retirement at Pfizer, a new CEO at B-MS and appointments at Mylan, Archimedes and Kinex – People on the move
Lamberto Andreotti has been appointed as CEO of Bristol-Myers Squibb. Andreotti will begin the role when James Cornelius retires as CEO. Cornelius will remain as chairman at the request of the B-MS’ board.
Andreotti has worked at B-MS for 12 years. Before joining the company he worked at KABI Pharmacia and Pharmacia & Upjohn.
Archimedes Pharma has secured £65m ($97m) in new funding and appointed a new CEO as it targets the US market. Jeffrey Buchalter has been named as president and CEO having recently resigned from the same positions at Enzon. Buchalter has also worked at Wyeth.
William Ringo, senior vice president (SVP), worldwide business development, strategy and innovation at Pfizer, is to retire. Ringo joined Pfizer in 2008, having spent 28 years at Eli Lilly, and is credited with helping the company connect with expanding opportunities in biotech.
Mylan has named John Sheehan as executive VP and chief financial officer. Sheehan has more than 30 years of experience in global corporate finance at companies including Delphi Automotive and KPMG.
Rudolf Kwan has joined Kinex Pharmaceuticals. Kwan has more than 20 years experience in clinical operations, most recently at Schering Plough. He has also worked at Chiron and SmithKline Beecham.
Aegate has appointed Trevor Jones to its executive board. Jones has more than 40 years experience in the pharma industry, holding positions at the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), Allergan and Synexus.
Stephen Hitchcock has been named as SVP, drug discovery at Envoy Therapeutics. Hitchcock joins Envoy from Amgen where he spent six years. He also worked at Eli Lilly for 10 years.
Garnet BioTherapeutics has appointed Sanjay Batra as SVP, development. Batra has more than 15 years experience in the pharma and biotech sectors, including nine years at Johnson & Johnson and a period at Bracco Diagnostics.
